RSV clinical trials at UCSF
2 research studies open to eligible people
RSV is a virus that can lead to lung infections and breathing problems. UCSF is researching a drug called EDP-938 for adults with RSV who are at high risk. UCSF is also studying azithromycin to see if it helps children with severe RSV breathing issues.
EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications.
open to eligible people ages 18 years and up
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Fresno, California and other locations
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
open to eligible people ages up to 2 years
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
San Francisco, California and other locations
Our lead scientists for RSV research studies include Matt Zinter, MD James Howard, MD.
Last updated: